Ticker: AZN

AstraZeneca

Pharma Healthcare Drug Manufacturers - General

Price 159.31

Reco Sell Potential 43 Risk 70 Updated 2026-09-09

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its core products include treatments in oncology, cardiovascular, renal, and respiratory diseases. Major business segments consist of pharmaceuticals and biologics, with primary revenue sources derived from product sales and collaborations. The company is recognized for its innovative therapies and strong pipeline of new drugs.

Investment Profile

AstraZeneca's investment profile is more aligned with value investors, given its stable revenue generation and moderate dividend yield. The stock may appeal to those seeking a balance between growth potential and income, although recent performance indicates some volatility. Investors should consider the company's risk factors and market conditions when evaluating its suitability for their portfolios.

Category: Pharma Sector: Healthcare Industry: Drug Manufacturers - General Investment style: Growth Horizon: Medium-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-09-10

EPS (TTM) — earnings per share for the last 12 months, $: 6.72
Revenue QoQ — quarter-over-quarter revenue growth: 0.6%
EPS surprise: 2.4%
20d volatility: 1.3%
Dividend yield: 2.1%
last ex-date: 2026-08-07

AI recommendation changes

Date	Before	After	Reason
2026-08-31	Hold	Sell	Weak momentum and high risk; hold for now.
2026-08-21	Sell	Hold	Weak momentum and high risk limit upside potential.
2026-07-14	Hold	Sell	Weak momentum and high risk; cautious approach advised.
2026-07-07	Buy	Hold	Weak fundamentals and mixed momentum signal caution.
2026-06-29	Hold	Buy	Strong recent performance and positive EPS surprise.
2026-05-24	Buy	Hold	Weak momentum and fundamentals suggest caution.
2026-05-22	Hold	Buy	Mixed momentum; fundamentals show slight weakness.
2026-05-20	Sell	Hold	Weak momentum and fundamentals suggest caution.
2026-05-08	—	Sell	Weak momentum and fundamentals raise significant risk concerns.
2026-05-07	Hold	Buy	Компания показывает сильный рост за последние 120 дней, несмотря на краткосрочные колебания. Дивидендная доходность и положительный сюрприз по EPS также поддерживают оптимистичный взгляд на акции.
2026-04-27	Buy	Hold	Компания показывает сильный рост за последние 60 и 120 дней, однако недавнее снижение на 7.35% за 5 дней и негативный сюрприз по доходам указывают на определенные риски.
2026-04-01	Hold	Buy	Компания демонстрирует сильный рост за последние 60 и 120 дней, что указывает на позитивные перспективы. Низкий уровень риска и стабильный дивиденд делают её привлекательной для инвестиций.
2026-03-25	Buy	Hold	Компания демонстрирует сильный рост за последние 60 и 120 дней, однако недавние падения на 10% за 20 дней и негативный сюрприз по прибыли вызывают опасения. Рекомендуется удерживать акции до прояснения ситуации.
2026-03-17	Hold	Buy	Компания демонстрирует сильный рост за последние 120 дней, однако недавние колебания цен и негативный сюрприз по доходам указывают на потенциальные риски. Рекомендуется удерживать акции до более ясных сигналов о восстано
2026-03-07	Buy	Hold	Компания показывает сильный рост за последние 60 и 120 дней, но недавнее снижение на 6.83% за 5 дней и значительное отрицательное значение сюрприза указывают на неопределенность в краткосрочной перспективе.
2026-01-25	Hold	Buy	Компания показывает положительную динамику на длительном горизонте, особенно за последние 120 дней, что свидетельствует о росте интереса инвесторов. Несмотря на краткосрочные колебания, AstraZeneca имеет потенциал для да

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2025-12-10	HSBC	Target Raised	95 → 108	179.64
2025-12-03	Morgan Stanley	Target Raised	93 → 103	180.34

News Page 1 of 2

AstraZeneca’s Tozorakimab Achieves Success in Late-Stage Trials for COPD Treatment, Boosting Sales Projections

09/08/2026, 05:37 AM business growth healthcare AstraZeneca

AstraZeneca's recent announcement of positive late-stage trial results for its COPD drug tozorakimab significantly enhances its market potential, with expectations for multibillion-dollar sales and FDA approval by early 2027.

AstraZeneca Considers Merger Talks with Bristol Myers Squibb, Challenging Decade-Long Pharma Strategy

08/06/2026, 03:36 AM business review AstraZeneca

AstraZeneca's reported merger talks with Bristol Myers Squibb signal a potential shift in the pharmaceutical industry's strategy, moving away from smaller acquisitions to larger-scale mergers. This could reshape AstraZeneca's market position but also presents significant integration and regulatory challenges.

Stocks Making Significant Moves Premarket: AstraZeneca, Bristol Myers Squibb, eBay, and More

08/03/2026, 05:37 AM business review Ferguson Enterprises Micron AstraZeneca Alibaba Microsoft Sandisk Seagate Technology eBay

Premarket trading saw significant movements in shares of several companies, notably AstraZeneca and Bristol Myers Squibb, following reports of merger talks, which impacted their stock prices in opposite directions.

AstraZeneca (AZN) Shares Fall 7% Amid Reports of $400 Billion Merger Talks with Bristol Myers Squibb (BMY)

08/03/2026, 12:37 AM stock_drop AstraZeneca

AstraZeneca's shares fell by 7% following reports of ongoing merger talks with Bristol Myers Squibb, potentially valuing the deal at around $400 billion. This significant drop reflects investor concerns about the implications of such a large merger in the pharmaceutical sector.

U.S. President Donald Trump Announces Resumption of Negotiations with Iran Amid Ongoing Geopolitical Tensions

08/03/2026, 12:37 AM announcement finance AstraZeneca Exxon Mobil Chevron Valero Energy

U.S. President Donald Trump's announcement of negotiations with Iran has renewed hopes for a diplomatic resolution to ongoing tensions, which could significantly impact global energy markets. This development follows a period of heightened military threats and fluctuating oil prices.

Markets Rally as Trump Cancels Iran Strike and OPEC+ Increases Oil Production

08/02/2026, 06:31 PM review energy AstraZeneca

President Trump's cancellation of a planned military strike on Iran, coupled with OPEC+'s decision to increase oil production, has led to a significant drop in oil prices and a positive shift in market sentiment, indicating potential stability in energy markets and broader economic implications.

AstraZeneca and Bristol Myers Squibb Explore $400 Billion Merger, According to Financial Times

08/02/2026, 01:31 PM business announcement AstraZeneca

AstraZeneca is exploring a potential merger with Bristol Myers Squibb, which could create a combined entity valued at approximately $400 billion, marking one of the largest mergers in history.

Analysts HSBC downgraded AstraZeneca (AZN) from Buy to Hold, citing a challenging outlook and reduced target price to £137.50

07/14/2026, 06:36 AM rating_drop Analysts: analysts, HSBC pharma AstraZeneca

HSBC has downgraded its rating for AstraZeneca from buy to hold, citing concerns over the company's future following a recent clinical trial failure that negatively impacted its stock price.

AstraZeneca’s Failed Wainua Trial Raises Concerns Over Pipeline Valuation Premium

07/10/2026, 10:30 PM business review pharma AstraZeneca

AstraZeneca's recent failure in a late-stage trial for its drug Wainua has raised concerns about the company's overall pipeline valuation, despite analysts estimating only a modest financial impact. The market's reaction suggests a reassessment of investor confidence in AstraZeneca's ability to deliver successful drug developments.

Stocks Making Significant Moves Midday: Micron, Mara Holdings, Paramount Skydance, and Others

07/09/2026, 09:36 AM business review Mara Holdings Micron Costco AstraZeneca Levi Strauss & Co PepsiCo Salesforce

Several companies experienced significant stock movements, with Micron Technology and Mara Holdings seeing notable gains, while Paramount Skydance and AstraZeneca faced declines due to legal and clinical trial setbacks, respectively.